{"url_path":"/sec/rgnx/8-k/2026-07-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1590877/0001193125-26-308342-index.html","accession_number":"0001193125-26-308342","cik":"0001590877","ticker":"RGNX","issuer_name":"REGENXBIO Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1590877/0001193125-26-308342-index.html","primary_entity_key":"0001590877","primary_entity_name":"REGENXBIO Inc."},"word_count":143,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNo.\n\n  \n\nDescription\n\n 1.1\n  \n[Underwriting Agreement, dated July 16, 2026, among REGENXBIO Inc. and Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Leerink Partners LLC and Mizuho Securities USA LLC, as representatives of the Underwriters.](d40931dex11.htm)\n\n 4.1\n  \n[Form of Pre-funded Warrant.](d40931dex41.htm)\n\n 5.1\n  \n[Opinion of Covington & Burling LLP.](d40931dex51.htm)\n\n23.1\n  \n[Consent of Covington & Burling LLP (included as part of Exhibit 5.1).](d40931dex51.htm)\n\n99.1\n  \n[Press release dated July 17, 2026.](d40931dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nREGENXBIO INC.\n\nDate: July 20, 2026\n \n\n \nBy:\n \n\n/s/ Patrick J. Christmas II\n\n \n\n \n\n \n\nPatrick J. Christmas II\n\nExecutive Vice President, Chief Strategy & Legal Officer"}